TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07008976: A Randomized, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breas

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 246 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,206,032

Rescue Site Savings

+$13,317,612

Unlock Full NCT07008976 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07008976 Rescue Dossier →